Metabolic syndrome

Last updated
Metabolic syndrome
Other namesDysmetabolic syndrome X
Obesity6.JPG
A man with marked central obesity, a hallmark of metabolic syndrome. His weight is 182 kg (400 lbs), height 185 cm (6 ft 1 in), and body mass index (BMI) 53 (normal 18.5 to 24.9).
Specialty Endocrinology
Symptoms Obesity
Differential diagnosis Acanthosis nigricans, erectile dysfunction, hyperuricemia, insulin resistance, nonalcoholic fatty liver disease, obesity, polycystic ovarian syndrome, prediabetes

Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL).

Contents

Metabolic syndrome is associated with the risk of developing cardiovascular disease and type 2 diabetes. [1] In the U.S., about 25% of the adult population has metabolic syndrome, a proportion increasing with age, particularly among racial and ethnic minorities. [2] [3]

Insulin resistance, metabolic syndrome, and prediabetes are closely related to one another and have overlapping aspects. The syndrome is thought to be caused by an underlying disorder of energy utilization and storage, but the cause of the syndrome is an area of ongoing medical research. Researchers debate whether a diagnosis of metabolic syndrome implies differential treatment or increases risk of cardiovascular disease beyond what is suggested by the sum of its individual components. [4]

Signs and symptoms

The key sign of metabolic syndrome is central obesity, also known as visceral, male-pattern or apple-shaped adiposity. It is characterized by adipose tissue accumulation predominantly around the waist and trunk. [5] Other signs of metabolic syndrome include high blood pressure, decreased fasting serum HDL cholesterol, elevated fasting serum triglyceride level, impaired fasting glucose, insulin resistance, or prediabetes. Associated conditions include hyperuricemia; fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease; polycystic ovarian syndrome in women and erectile dysfunction in men; and acanthosis nigricans. [6]

Neck circumference

Neck circumference has been used as a simple surrogate index of upper-body subcutaneous fat. Values >40.25 cm (15.85 in) (men) and >35.75 cm (14.07 in) (women) are considered high risk for metabolic syndrome, and large neck circumference more than doubles risk. [7] In adults with overweight/obesity, clinically significant weight loss may protect against COVID-19, [8] and neck circumference has been associated with increased risk of mechanical ventilation and mortality in hospitalized COVID-19 patients. [9] [10]

Complications

Metabolic syndrome can lead to type 2 diabetes, cardiovascular diseases, stroke, kidney disease and nonalcoholic fatty liver disease. [11] It is also associated with a significantly increased risk of surgical complications across most types of surgery in a 2023 systematic review and meta-analysis of >13 million individuals. [12]

Causes

The mechanisms underlying metabolic syndrome are under investigation and only partially elucidated. Most affected people are older, obese, sedentary, and have some degree of insulin resistance. Stress can also contribute. Important risk factors include diet (particularly sugar-sweetened beverages), [13] genetics, [14] [15] [16] [17] aging, sedentary behaviour [18] or low physical activity, [19] [20] disrupted chronobiology/sleep, [21] mood disorders and some medications, [22] [23] and excessive alcohol use. [24] The pathogenic role of excessive adipose expansion under sustained overeating and resulting lipotoxicity has also been proposed. [25]

Markers of systemic inflammation including C-reactive protein, fibrinogen, interleukin 6, and tumor necrosis factor-alpha  (TNF-α) are often increased. Some research has focused on increased uric acid levels from dietary fructose. [26] [27] [28]

Modern "Western diet" patterns with high intake of energy-dense processed foods are a factor in the development of metabolic syndrome. [29] Rather than total adiposity, the core clinical component is visceral/ectopic fat, and the principal metabolic abnormality is insulin resistance. [30] A chronic energy surplus unmatched by activity may lead to mitochondrial dysfunction and insulin resistance. [31]

Stress

Prolonged chronic stress may contribute to metabolic syndrome via dysregulation of the hypothalamic–pituitary–adrenal axis. [32] Elevated cortisol can raise glucose and insulin levels, promoting visceral adiposity, insulin resistance, dyslipidaemia, and hypertension, and has effects on bone turnover. [33] [34] [35]

Pathophysiology

It is common for there to be a development of visceral fat, after which adipocytes increase plasma levels of TNF-α and alter levels of other adipokines (e.g., adiponectin, resistin, PAI-1). TNF-α can induce inflammatory cytokines and may trigger insulin resistance. [36] Rat models with high-sucrose diets have shown progression from hypertriglyceridaemia to visceral fat accumulation and insulin resistance. Increased adipose tissue elevates immune cells and chronic inflammation, contributing to hypertension, atherosclerosis and diabetes. [37] [38]

The endocannabinoid system may contribute to metabolic dysregulation. [39] [40] [41] Overproduction can alter reward circuitry and executive function, perpetuating unhealthy behaviours.[ medical citation needed ] The brain modulates peripheral carbohydrate and lipid metabolism. [39] [40] Overfeeding with sucrose/fructose, particularly with high-fat intake, can induce features of metabolic syndrome in animals. [42] Arachidonic acid–derived mediators (eicosanoids; 2-arachidonoylglycerol; anandamide) may link lipid oversupply and inflammation. [43] [41]

Diagnosis

NCEP

As of 2023, the U.S. National Cholesterol Education Program Adult Treatment Panel III (2001) remains widely used. [4] It requires at least three of the following: [44]

2009 Interim Joint Statement

The International Diabetes Federation Task Force and partner organisations harmonised criteria in 2009. [45] Diagnosis is three or more of:

This statement recognises population differences in waist risk thresholds and encourages common criteria with agreed cut points for international comparisons. [45]

The prior IDF and revised NCEP definitions are similar, but differ on assumptions when body mass index ≥30 kg/m2 and on geography-specific waist cut points.[ citation needed ]

WHO

The World Health Organization (1999) [46] requires one of diabetes mellitus, impaired glucose tolerance, impaired fasting glucose or insulin resistance and two of:

EGIR

The European Group for the Study of Insulin Resistance (1999) requires insulin resistance (top 25% fasting insulin among nondiabetic individuals) and two or more of: [47]

Cardiometabolic index

The Cardiometabolic Index (CMI) estimates risk of type 2 diabetes, non-alcoholic fatty liver disease, and metabolic issues from waist-to-height ratio and triglycerides-to-HDL-C ratio. [48] CMI has also been explored alongside cardiovascular disease and erectile dysfunction. [49] Anti-inflammatory dietary patterns may improve related markers. [50]

Other

High-sensitivity C-reactive protein is used to predict cardiovascular risk in metabolic syndrome and may predict nonalcoholic fatty liver disease. [51] Reproductive disorders (such as polycystic ovary syndrome in women of reproductive age) and erectile dysfunction or decreased total testosterone in men have also been associated. [52]

Prevention

Prevention of metabolic syndrome centres on improving modifiable lifestyle factors that contribute to excess visceral fat, insulin resistance, and cardiometabolic risk. Even modest, sustained changes in activity and diet have been shown to improve multiple components of the syndrome. [53] [54]

Regular physical activity is strongly supported by clinical and public-health organizations. Guidelines from the American Heart Association recommend at least 150 minutes per week of moderate-intensity aerobic activity, or 75 minutes of vigorous activity, with additional muscle-strengthening exercises on two or more days per week. [55] Walking—even in shorter bouts that accumulate to 30 minutes per day—is associated with measurable improvements in blood pressure, insulin sensitivity, and waist circumference. [54]

Dietary patterns emphasizing whole foods appear beneficial. Evidence from observational studies and randomized trials supports Mediterranean-style eating, which is associated with reduced central adiposity and improved lipid and glycaemic measures. [56] Calorie reduction, improved diet quality, and lowering intake of refined carbohydrates also contribute to improved metabolic parameters. [57] Time-restricted eating (a form of intermittent fasting) has shown preliminary benefits in reducing waist circumference and fasting glucose in adults with metabolic syndrome, though long-term effects remain under investigation. [58]

Other behavioural factors influence prevention outcomes. Adequate sleep duration and quality have been linked to lower cardiometabolic risk, with insufficient sleep associated with higher rates of hypertension, obesity, and dysregulated glucose metabolism. [59] Reducing alcohol intake may also be protective, as heavy use can worsen hepatic and metabolic outcomes in people with underlying metabolic risk. [60]

Although individual-level changes are effective for many people, adherence varies widely in real-world settings. [57] Public-health bodies—including the International Obesity Taskforce—argue that sustained prevention requires population-level interventions, such as improved access to healthy foods, urban design that supports physical activity, and policies addressing socioeconomic drivers of obesity. [61]

Management

Management focuses on reducing cardiovascular and metabolic risk through lifestyle modification, pharmacologic therapy, and, in selected cases, surgery. [54] Because metabolic syndrome represents a cluster of interrelated conditions, treatment typically targets each component individually rather than the syndrome as a single entity. [62]

Diet and meal timing

A Mediterranean-style eating pattern—emphasising vegetables, fruits, whole grains, legumes, nuts, and unsaturated fats—is associated with improvements in blood pressure, lipids, insulin sensitivity, and cardiovascular risk. [56] Reduced-carbohydrate approaches may lower glucose and promote weight loss in insulin-resistant individuals. [57] Evidence on meal timing suggests time-restricted eating or avoidance of late-night meals can modestly improve glycaemic and lipid markers, though long-term data are limited. [58] Guidance recommends tailoring dietary advice to personal preference, culture, and access to improve adherence. [54]

Follow-up and equity considerations

Ongoing follow-up includes monitoring waist circumference, body weight, blood pressure, lipids, and fasting glucose or HbA1c. [54] Recent guidance emphasises equitable care through culturally appropriate counselling, affordable medication access, and community-based support. [63]

Medications and therapies

Treatment of individual risk factors follows established cardiovascular and diabetes guidelines. [62]

Physical activity and weight reduction

Weight loss of ~7–10% over 6–12 months improves BP, lipids, and insulin sensitivity. [54] Public-health guidance advises ≥150 min/week moderate aerobic activity (or 75 min vigorous) plus muscle-strengthening ≥2 days/week. [55]

Sleep, tobacco, and alcohol

Inadequate/irregular sleep and untreated obstructive sleep apnoea increase metabolic and CV risk. [59] Smoking increases insulin resistance and CV risk; cessation reduces adverse outcomes. [62] High alcohol intake raises BP, TGs, and hepatic steatosis; moderation is advised. [60]

Surgery

Metabolic (bariatric) surgery is considered when lifestyle and pharmacotherapy are insufficient. Surgery is associated with durable weight loss and partial or complete remission of type 2 diabetes, hypertension, and dyslipidaemia. [67] Guidelines endorse surgery for BMI ≥35 kg/m², or ≥30 kg/m² with metabolic complications. [68]

Epidemiology

Approximately 20–25% of the world's adults have metabolic syndrome. [61] In 2000, ~32% of U.S. adults met criteria; [69] [70] more recent estimates are ~34%. [70] [71]

In young children, there is no consensus on measurement; age-specific cut points are not well established. [72] Continuous risk scores are often used instead. [73] Microbiome composition and some conditions have been associated with metabolic syndrome, sometimes with gender-specific patterns. [74] [75]

History

In 1921, Joslin reported the association of diabetes with hypertension and hyperuricaemia. [76] In 1923, Kylin expanded on this triad. [77] In 1947, Vague observed that upper-body obesity predisposed to diabetes, atherosclerosis, gout and calculi. [78] The term metabolic syndrome began appearing in the late 1950s. In 1967, Avogaro, Crepaldi and coworkers described moderately obese people with diabetes, hypercholesterolemia, and marked hypertriglyceridemia that improved on hypocaloric, low-carbohydrate diets. [79] In 1977, Haller used the term for associations of obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia, and hepatic steatosis. [80] The same year, Singer used it for associations of obesity, gout, diabetes, and hypertension with hyperlipoproteinemia. [81] In 1977–1978, Gerald B. Phillips proposed a "constellation of abnormalities" (glucose intolerance, hyperinsulinemia, hypercholesterolemia, hypertriglyceridemia, hypertension) and hypothesised sex hormones as a linking factor. [82] [83] In 1988, Gerald M. Reaven's Banting lecture proposed insulin resistance as the underlying factor and coined syndrome X. [84]

See also

References

  1. ↑ "Metabolic syndrome". Mayo Clinic. Retrieved 10 Sep 2020.
  2. ↑ Falkner B, Cossrow ND (July 2014). "Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States". Current Hypertension Reports. 16 (7) 449. doi:10.1007/s11906-014-0449-5. PMC   4083846 . PMID   24819559.
  3. ↑ Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S (August 2013). "Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010". Journal of the American College of Cardiology. 62 (8): 697–703. doi:10.1016/j.jacc.2013.05.064. PMC   3756561 . PMID   23810877.
  4. 1 2 Anagnostis, Panagiotis (November 30, 2023). "Metabolic Syndrome". BMJ Best Practice. Retrieved 30 December 2023.
  5. ↑ "Metabolic Syndrome". Diabetes.co.uk. 15 January 2019.
  6. ↑ Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill MA, et al. (March 2018). "Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic". Toxicological Sciences. 162 (1): 36–42. doi:10.1093/toxsci/kfx233. PMC   6256950 . PMID   29106690.
  7. ↑ Mohseni-Takalloo, Sahar; Mozaffari-Khosravi, Hassan; Mohseni, Hadis; Mirzaei, Masoud; Hosseinzadeh, Mahdieh (2023-06-13). "Evaluating Neck Circumference as an Independent Predictor of Metabolic Syndrome and Its Components Among Adults: A Population-Based Study". Cureus. 15 (6) e40379. doi: 10.7759/cureus.40379 . ISSN   2168-8184. PMC   10344419 . PMID   37456431.
  8. ↑ Shyam, Sangeetha; García-Gavilán, Jesús Francisco; Paz-Graniel, Indira; Gaforio, José J.; Martínez-González, Miguel Ángel; Corella, Dolores; Martínez, J. Alfredo; Alonso-Gómez, Ángel M.; Wärnberg, Julia; Vioque, Jesús; Romaguera, Dora; López-Miranda, José; Estruch, Ramon; Tinahones, Francisco J.; Lapetra, José (2023-10-13). "Association of adiposity and its changes over time with COVID-19 risk in older adults with overweight/obesity and metabolic syndrome: a longitudinal evaluation in the PREDIMED-Plus cohort". BMC Medicine. 21 (1): 390. doi: 10.1186/s12916-023-03079-z . ISSN   1741-7015. PMC   10576302 . PMID   37833678.
  9. ↑ Di Bella, Stefano; Cesareo, Roberto; De Cristofaro, Paolo; Palermo, Andrea; Sanson, Gianfranco; Roman-Pognuz, Erik; Zerbato, Verena; Manfrini, Silvia; Giacomazzi, Donatella; Dal Bo, Eugenia; Sambataro, Gianluca; Macchini, Elisabetta; Quintavalle, Francesco; Campagna, Giuseppe; Masala, Renato (2021). "Neck circumference as reliable predictor of mechanical ventilation support in adult inpatients with COVID-19: A multicentric prospective evaluation". Diabetes/Metabolism Research and Reviews. 37 (1) e3354. doi:10.1002/dmrr.3354. ISSN   1520-7552. PMC   7300447 . PMID   32484298.
  10. ↑ Di Bella, Stefano; Zerbato, Verena; Sanson, Gianfranco; Roman-Pognuz, Erik; De Cristofaro, Paolo; Palermo, Andrea; Valentini, Michael; Gobbo, Ylenia; Jaracz, Anna Wladyslawa; Bozic Hrzica, Elizabeta; Bresani-Salvi, Cristiane Campello; Galindo, Alexandre Bezerra; Crovella, Sergio; Luzzati, Roberto (2021-12-10). "Neck Circumference Predicts Mortality in Hospitalized COVID-19 Patients". Infectious Disease Reports. 13 (4): 1053–60. doi: 10.3390/idr13040096 . ISSN   2036-7449. PMC   8700782 . PMID   34940406.
  11. ↑ "Metabolic syndrome – Symptoms and causes". Mayo Clinic. Retrieved 2022-03-31.
  12. ↑ Norris, Philip; Gow, Jeff; Arthur, Thomas; Conway, Aaron; Fleming, Fergal J; Ralph, Nicholas (2 November 2023). "Metabolic syndrome and surgical complications: A systematic review and meta-analysis of 13 million individuals". International Journal of Surgery. 110 (1): 541–53. doi: 10.1097/JS9.0000000000000834 . PMC   10793842 . PMID   37916943.
  13. ↑ Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB (November 2010). "Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis". Diabetes Care. 33 (11): 2477–83. doi:10.2337/dc10-1079. PMC   2963518 . PMID   20693348.
  14. ↑ Pollex RL, Hegele RA (September 2006). "Genetic determinants of the metabolic syndrome". Nature Clinical Practice Cardiovascular Medicine. 3 (9): 482–89. doi:10.1038/ncpcardio0638. PMID   16932765.
  15. ↑ Poulsen P, Vaag A, Kyvik K, Beck-Nielsen H (May 2001). "Genetic versus environmental aetiology of the metabolic syndrome among male and female twins". Diabetologia. 44 (5): 537–43. doi: 10.1007/s001250051659 . PMID   11380071. S2CID   26582450.
  16. ↑ Groop L (March 2000). "Genetics of the metabolic syndrome". The British Journal of Nutrition. 83 (Suppl 1): S39 –S48. doi: 10.1017/S0007114500000945 . PMID   10889791. S2CID   8974554.
  17. ↑ Bouchard C (May 1995). "Genetics and the metabolic syndrome". International Journal of Obesity and Related Metabolic Disorders. 19 (Suppl 1): S52–59. PMID   7550538.
  18. ↑ Edwardson CL, Gorely T, Davies MJ, Gray LJ, Khunti K, Wilmot EG, Yates T, Biddle SJ (2012). "Association of sedentary behaviour with metabolic syndrome: a meta-analysis". PLOS ONE. 7 (4) e34916. Bibcode:2012PLoSO...734916E. doi: 10.1371/journal.pone.0034916 . PMC   3325927 . PMID   22514690.
  19. ↑ Katzmarzyk PT, Leon AS, Wilmore JH, Skinner JS, Rao DC, Rankinen T, Bouchard C (October 2003). "Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study". Medicine and Science in Sports and Exercise. 35 (10): 1703–09. doi: 10.1249/01.MSS.0000089337.73244.9B . PMID   14523308. S2CID   25598917.
  20. ↑ He D, Xi B, Xue J, Huai P, Zhang M, Li J (June 2014). "Association between leisure time physical activity and metabolic syndrome: a meta-analysis of prospective cohort studies". Endocrine. 46 (2): 231–40. doi:10.1007/s12020-013-0110-0. PMID   24287790. S2CID   5271746.
  21. ↑ Xi B, He D, Zhang M, Xue J, Zhou D (August 2014). "Short sleep duration predicts risk of metabolic syndrome: a systematic review and meta-analysis". Sleep Medicine Reviews. 18 (4): 293–97. doi:10.1016/j.smrv.2013.06.001. PMID   23890470.
  22. ↑ Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchell AJ, De Herdt A, Probst M, Scheewe TW, De Hert M (July 2014). "Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables" . Psychological Medicine. 44 (10): 2017–28. doi:10.1017/S0033291713002778. PMID   24262678. S2CID   206253750.
  23. ↑ Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, Probst M, De Hert M (March 2013). "Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators". The American Journal of Psychiatry. 170 (3): 265–74. doi:10.1176/appi.ajp.2012.12050620. PMID   23361837.
  24. ↑ Sun K, Ren M, Liu D, Wang C, Yang C, Yan L (August 2014). "Alcohol consumption and risk of metabolic syndrome: a meta-analysis of prospective studies". Clinical Nutrition. 33 (4): 596–602. doi:10.1016/j.clnu.2013.10.003. PMID   24315622.
  25. ↑ Vidal-Puig A (2013). "Adipose tissue expandability, lipotoxicity and the metabolic syndrome". Endocrinologia y Nutricion. 60 (Suppl 1): 39–43. doi:10.1016/s1575-0922(13)70026-3. PMID   24490226.
  26. ↑ Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ (March 2006). "A causal role for uric acid in fructose-induced metabolic syndrome". American Journal of Physiology. Renal Physiology. 290 (3): F625–31. doi:10.1152/ajprenal.00140.2005. PMID   16234313.
  27. ↑ Hallfrisch J (June 1990). "Metabolic effects of dietary fructose". FASEB Journal. 4 (9): 2652–60. doi: 10.1096/fasebj.4.9.2189777 . PMID   2189777. S2CID   23659634.
  28. ↑ Reiser S, Powell AS, Scholfield DJ, Panda P, Ellwood KC, Canary JJ (May 1989). "Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch". The American Journal of Clinical Nutrition. 49 (5): 832–39. doi: 10.1093/ajcn/49.5.832 . PMID   2497634.
  29. ↑ Bremer AA, Mietus-Snyder M, Lustig RH (March 2012). "Toward a unifying hypothesis of metabolic syndrome". Pediatrics. 129 (3): 560. doi:10.1542/peds.2011-2912. PMC   3289531 . PMID   22351884.
  30. ↑ Ali ES, Hua J, Wilson CH, Tallis GA, Zhou FH, Rychkov GY, Barritt GJ (September 2016). "The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1863 (9): 2135–46. doi:10.1016/j.bbamcr.2016.05.006. PMID   27178543.
  31. ↑ Bremer, A. A.; Mietus-Snyder, M.; Lustig, R. H. (2012). "Toward a Unifying Hypothesis of Metabolic Syndrome". Pediatrics. 129 (3): 557–570. doi:10.1542/peds.2011-2912. PMC   3289531 . PMID   22351884.
  32. ↑ Gohil BC, Rosenblum LA, Coplan JD, Kral JG (July 2001). "Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity". CNS Spectrums. 6 (7): 581–86, 589. doi:10.1017/s1092852900002121. PMID   15573024. S2CID   22734016.
  33. ↑ Tsigos C, Chrousos GP (October 2002). "Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress". Journal of Psychosomatic Research. 53 (4): 865–71. doi:10.1016/S0022-3999(02)00429-4. PMID   12377295.
  34. ↑ Rosmond R, Björntorp P (February 2000). "The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke". Journal of Internal Medicine. 247 (2): 188–97. doi: 10.1046/j.1365-2796.2000.00603.x . PMID   10692081. S2CID   20336259.
  35. ↑ Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, Kumari M, Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A, Lowe GD, Stansfeld SA, Marmot MG (November 2002). "Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study". Circulation. 106 (21): 2659–65. doi: 10.1161/01.cir.0000038364.26310.bd . PMID   12438290. S2CID   5992769.
  36. ↑ Hotamisligil GS (June 1999). "The role of TNFalpha and TNF receptors in obesity and insulin resistance". Journal of Internal Medicine. 245 (6): 621–25. doi: 10.1046/j.1365-2796.1999.00490.x . PMID   10395191. S2CID   58332116.
  37. ↑ Whitney, Ellie; Ralfes, R. Sharon. 2011. Understanding Nutrition. Wadsworth Cengage Learning: Belmont, CA.
  38. ↑ Paley, Carole A.; Johnson, Mark I. (2018). "Abdominal obesity and metabolic syndrome: exercise as medicine?". BMC Sports Sci Med Rehabil. 10 7. doi: 10.1186/s13102-018-0097-1 . ISSN   2052-1847. PMC   5935926 . PMID   29755739.
  39. 1 2 Gatta-Cherifi B, Cota D (2015). "Endocannabinoids and Metabolic Disorders". Endocannabinoids. Handbook of Experimental Pharmacology. Vol. 231. pp. 367–91. doi:10.1007/978-3-319-20825-1_13. ISBN   978-3-319-20824-4. PMID   26408168.
  40. 1 2 Vemuri VK, Janero DR, Makriyannis A (March 2008). "Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome". Physiology & Behavior. 93 (4–5): 671–86. doi:10.1016/j.physbeh.2007.11.012. PMC   3681125 . PMID   18155257. ...
  41. 1 2 Turcotte C, Chouinard F, Lefebvre JS, Flamand N (June 2015). "Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites". Journal of Leukocyte Biology. 97 (6): 1049–70. doi:10.1189/jlb.3RU0115-021R. PMID   25877930. S2CID   206999921.
  42. ↑ Fukuchi S, Hamaguchi K, Seike M, Himeno K, Sakata T, Yoshimatsu H (June 2004). "Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats". Experimental Biology and Medicine. 229 (6): 486–93. doi:10.1177/153537020422900606. PMID   15169967. S2CID   20966659.
  43. ↑ Di Marzo V, Fontana A, Cadas H, et al. (Dec 1994). "Formation and inactivation of endogenous cannabinoid anandamide in central neurons". Nature (Submitted manuscript). 372 (6507): 686–91. Bibcode:1994Natur.372..686D. doi:10.1038/372686a0. PMID   7990962. S2CID   4341716.
  44. ↑ Expert Panel On Detection, Evaluation (May 2001). "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults". JAMA. 285 (19): 2486–97. doi:10.1001/jama.285.19.2486. PMID   11368702.
  45. 1 2 3 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC (October 2009). "Harmonizing the metabolic syndrome: a joint interim statement..." Circulation. 120 (16): 1640–45. doi:10.1161/CIRCULATIONAHA.109.192644. PMID   19805654.
  46. ↑ Alberti KG, et al. (1999). "Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications" (PDF). World Health Organization. pp. 32–33 (PDF). Retrieved 25 March 2013.{{cite web}}: Check |archive-url= value (help)
  47. ↑ Balkau B, Charles MA (May 1999). "Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)". Diabet Med. 16 (5): 442–43. doi:10.1046/j.1464-5491.1999.00059.x. PMID   10342346.
  48. ↑ Pluta, Waldemar; Dudzińska, Wioleta; Lubkowska, Anna (2022-01-06). "Metabolic Obesity in People with Normal Body Weight (MONW) – Review of Diagnostic Criteria". International Journal of Environmental Research and Public Health. 19 (2). MDPI AG: 624. doi: 10.3390/ijerph19020624 . ISSN   1660-4601. PMC   8776153 . PMID   35055447.
  49. ↑ Chen, Lei; Shi, Guang-rui; Huang, Dan-dan; Li, Yang; Ma, Chen-chao; Shi, Min; Su, Bin-xiao; Shi, Guang-jiang (2019). "Male sexual dysfunction: A review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention". Biomedicine & Pharmacotherapy. 112 108585. Elsevier BV. doi: 10.1016/j.biopha.2019.01.046 . ISSN   0753-3322. PMID   30798136.
  50. ↑ Bagheri, Soghra; Zolghadri, Samaneh; Stanek, Agata (2022-09-26). "Beneficial Effects of Anti-Inflammatory Diet in Modulating Gut Microbiota and Controlling Obesity". Nutrients. 14 (19). MDPI AG: 3985. doi: 10.3390/nu14193985 . ISSN   2072-6643. PMC   9572805 . PMID   36235638.
  51. ↑ Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K (2009). "High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population". Journal of Gastroenterology. 44 (4): 313–21. doi:10.1007/s00535-009-0002-5. PMID   19271113.
  52. ↑ Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT (February 2011). "Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies". International Journal of Epidemiology. 40 (1): 189–207. doi: 10.1093/ije/dyq158 . PMID   20870782.
  53. 1 2 American Diabetes Association (2024). "Standards of Care in Diabetes—2024". Diabetes Care. 47 (Suppl 1): S50 –S65. doi:10.2337/dc24-S003. PMC   10725807 . PMID   38078581.
  54. 1 2 3 4 5 6 Peterseim, CM (2024). "Metabolic syndrome: an updated review on diagnosis and treatment". J Prim Care Community Health. 15 21501319241309168. doi:10.1177/21501319241309168. PMC   11672556 . PMID   39714021.
  55. 1 2 "AHA recommendations for physical activity in adults". American Heart Association. 10 March 2024. Retrieved 12 November 2025.
  56. 1 2 Dominguez, LJ (2023). "Mediterranean diet in the management and prevention of metabolic syndrome". Nutrition Metab Cardiovasc Dis. 33 (7): 1588–1598. doi:10.1016/j.numecd.2023.05.007. PMID   37336718.
  57. 1 2 3 Feinman, RD (2015). "Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base". Nutrition. 31 (1): 1–13. doi:10.1016/j.nut.2014.06.011. PMID   25287761.
  58. 1 2 Manoogian, ENC (2024). "Time-restricted eating in adults with metabolic syndrome". Ann Intern Med. 177 (4): 556–565. doi:10.7326/M24-0859. PMC   11929607 . PMID   39348690.
  59. 1 2 Eshera, YM (2023). "Sleep is essential for cardiovascular health". Curr Probl Cardiol. 48 (4) 101042. doi:10.1016/j.cpcardiol.2023.101042 (inactive 14 November 2025).{{cite journal}}: CS1 maint: DOI inactive as of November 2025 (link)
  60. 1 2 Hagström, H (2024). "Interactions between metabolic syndrome and alcohol consumption increase liver disease risk". United European Gastroenterol J. 12 (2): 168–176. doi:10.1002/ueg2.12524. PMC   10954435 . PMID   38381115.
  61. 1 2 "Metabolic syndrome". International Diabetes Federation. Retrieved 12 November 2025.
  62. 1 2 3 4 Swarup, S (2024). "Management". Metabolic Syndrome. Treasure Island, FL: StatPearls Publishing.
  63. ↑ Giangregorio, F (2024). "A systematic review of metabolic syndrome: key findings and practical insights". J Clin Med. 13 (8): 2800. doi: 10.3390/jcm13082800 (inactive 14 November 2025).{{cite journal}}: CS1 maint: DOI inactive as of November 2025 (link)
  64. ↑ Grundy, SM (2005). "Diagnosis and management of the metabolic syndrome". Circulation. 112 (17): 2735–2752. doi:10.1161/CIRCULATIONAHA.105.169404. PMID   16157765.
  65. ↑ Wilding, JPH (2021). "Once-weekly semaglutide in adults with overweight or obesity". N Engl J Med. 384 (11): 989–1002. doi:10.1056/NEJMoa2032183. PMID   33567185.
  66. ↑ Frias, JP (2022). "Tirzepatide once weekly for the treatment of obesity". N Engl J Med. 387 (3): 205–216. doi:10.1056/NEJMoa2206038. PMID   35658024.
  67. ↑ Mirghani, H (2023). "Metabolic surgery versus usual care: effects on diabetes and metabolic risk". Diabetol Metab Syndr. 15 (1): 1001. doi: 10.1186/s13098-023-01001-4 . PMC   9951503 . PMID   36829204.
  68. ↑ Angrisani, L (2023). "Bariatric surgery worldwide 2023 update". Obes Surg. 33 (12): 3962–3974. doi:10.1136/bmjdrc-2023-003558. PMC   10503393 . PMID   37699720.
  69. ↑ Ford ES, Li C, Zhao G (September 2010). "Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US". Journal of Diabetes. 2 (3): 180–93. doi: 10.1111/j.1753-0407.2010.00078.x . PMID   20923483. S2CID   5145131.
  70. 1 2 Ford ES, Giles WH, Mokdad AH (October 2004). "Increasing prevalence of the metabolic syndrome among U.S. Adults". Diabetes Care. 27 (10): 2444–49. doi: 10.2337/diacare.27.10.2444 . PMID   15451914.
  71. ↑ Mozumdar A, Liguori G (January 2011). "Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006". Diabetes Care. 34 (1): 216–19. doi:10.2337/dc10-0879. PMC   3005489 . PMID   20889854.
  72. ↑ Kamel M, Smith BT, Wahi G, Carsley S, Birken CS, Anderson LN (December 2018). "Continuous cardiometabolic risk score definitions in early childhood: a scoping review". Obesity Reviews. 19 (12): 1688–99. doi:10.1111/obr.12748. PMID   30223304. S2CID   52291692.
  73. ↑ Chiarelli F, Mohn A (October 2017). "Early diagnosis of metabolic syndrome in children". The Lancet. Child & Adolescent Health. 1 (2): 86–88. doi:10.1016/S2352-4642(17)30043-3. PMID   30169210.
  74. ↑ Fan, Yong; Pedersen, Oluf (January 2021). "Gut microbiota in human metabolic health and disease" . Nature Reviews Microbiology. 19 (1): 55–71. doi:10.1038/s41579-020-0433-9. ISSN   1740-1526. PMID   32887946. S2CID   256744684.
  75. ↑ Pietropaoli, Davide; Altamura, Serena; Ortu, Eleonora; Guerrini, Luca; Pizarro, Theresa T.; Ferri, Claudio; Del Pinto, Rita (2023-04-10). "Association between metabolic syndrome components and gingival bleeding is women-specific: a nested cross-sectional study". Journal of Translational Medicine. 21 (1): 252. doi: 10.1186/s12967-023-04072-z . ISSN   1479-5876. PMC   10088168 . PMID   37038173.
  76. ↑ Joslin E (1921). "The Prevention of Diabetes Mellitus". JAMA. 76 (2): 79–84. doi:10.1001/jama.1921.02630020001001.
  77. ↑ Kylin E (1923). "[Studies of the hypertension-hyperglycemia-hyperuricemia syndrome]". Zentralbl Inn Med (in German). 44: 105–27.
  78. ↑ Vague J (1947). "La différenciation sexuelle, facteur déterminant des formes de l'obésité". Presse Med. 30: 339–40.
  79. ↑ Avogaro P, Crepaldi G, Enzi G, Tiengo A (1967). "Associazione di iperlipemia, diabete mellito e obesita' di medio grado" [Association of hyperlipemia, diabetes mellitus and middle-degree obesity]. Acta Diabetologica Latina (in Italian). 4 (4): 572–90. doi:10.1007/BF01544100. S2CID   25839940.
  80. ↑ Haller H (April 1977). "[Epidermiology and associated risk factors of hyperlipoproteinemia]". Zeitschrift für Sie Gesamte Innere Medizin und Ihre Grenzgebiete. 32 (8): 124–28. PMID   883354.
  81. ↑ Singer P (May 1977). "[Diagnosis of primary hyperlipoproteinemias]". Zeitschrift für die Gesamte Innere Medizin und Ihre Grenzgebiete. 32 (9): 129–33. PMID   906591.
  82. ↑ Phillips GB (July 1978). "Sex hormones, risk factors and cardiovascular disease". The American Journal of Medicine. 65 (1): 7–11. doi:10.1016/0002-9343(78)90685-X. PMID   356599.
  83. ↑ Phillips GB (April 1977). "Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction". Proceedings of the National Academy of Sciences of the United States of America. 74 (4): 1729–33. Bibcode:1977PNAS...74.1729P. doi: 10.1073/pnas.74.4.1729 . PMC   430867 . PMID   193114.
  84. ↑ Reaven GM (December 1988). "Banting lecture 1989. Role of insulin resistance in human disease". Diabetes. 37 (12): 1595–607. doi:10.2337/diabetes.37.12.1595. PMID   3056758.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.